Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 9Sarcoma 5Lymphoid 4Plasma cell 3Other hematologic neoplasm 3Head & Neck 3CNS 3Thoracic 2Gynecologic 2Gastrointestinal 2Endocrine 2Dermatologic 2Genitourinary 1Breast 1

Conditions

Prostatic Neoplasms 4397Urinary Bladder Neoplasms 1078Carcinoma, Renal Cell 1040Kidney Neoplasms 567Breast Neoplasms 453Neoplasms 402Carcinoma, Transitional Cell 297Neoplasm Metastasis 250Lung Neoplasms 242Testicular Neoplasms 202Melanoma 194Colorectal Neoplasms 193Ovarian Neoplasms 163Carcinoma, Non-Small-Cell Lung 150Sarcoma 134Non-Muscle Invasive Bladder Neoplasms 134Pancreatic Neoplasms 124Colonic Neoplasms 121Head and Neck Neoplasms 116Uterine Cervical Neoplasms 115Wilms Tumor 108Recurrence 106Motor Activity 100Stomach Neoplasms 89Urologic Neoplasms 88Neuroblastoma 88Disease 85Multiple Myeloma 83Carcinoma, Hepatocellular 79Adenocarcinoma 78

Interventions

temsirolimus 1Valproic Acid 1Sirolimus 1Immunoglobulin G 1Disulfides 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Erdheim-Chester Disease × Genitourinary × Clear all
NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡